mal

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231

Attorney Docket No.: 15303-000510

Client Reference No.: 51838AUSM1

6560 RECEIVED SEP 1 2 2002

TECH CENTER 1600/290

END and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alan R. Brooks, et al.

Application No.: 09/803,472

Filed: March 9, 2001

For: NOVEL ESTROGEN-

REGULATED G PROTEIN GAMMA SUBUNIT: COMPOSITIONS AND

METHODS OF USE

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Alan R. Brooks, et al. Application No.: 09/803,472

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Hugenia Garrett-Wackowski Reg. No. 37,330

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 925-472-5000 Fax: 925-472-8895

EGW:lls WC 9046021 v1 Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Filing Date

Application Number

PTO/SB/08B (10-01)

Complete if Known

March 9, 2001

09/803,472

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

OWN EMENT BY ALL CICAN			First Named Inventor	Brooks, Alan R.	
			Art Unit	1645	
	(use as man	y sheets as necessary)	Examiner Name	Unassigned	cq* (
Sheet	<u> </u>	of 1	Attorney Docket Number	15303-000510	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book manazine journal social symposium patricle (when appropriate), title of	
	1	BOCCHINFUSO et al., Cancer Res., 59:1869-1876 (1999)	
	2	COUSE et al., Endocr. Rev., 20(3):358-417 (1999)	
	3	COUSE et al., Science, 286:2328-2331 (1999)	
	4	DOWNES et al., Genomics, 57:173-176 (1999)	
	5	KORACH, Science, 266:1524-1527 (1994)	
	6	KOZAK, J. Cell Biol., 108:229-241 (1989)	
	7	KREGE et al., Proc. Natl. Acad. Sci. USA, 95:15677-15682 (1998)	
	8	KUIPER et al., Endocrinology, 138(3):863-870 (1997)	
	9	LeMELLAY et al., J. Cell. Biochem., 75:138-146 (1999)	
	10	MORISHATA et al., j. Biol. Chem., 270(49):29469-29475 (1995)	
	11	NURNBERG et al., Eur. J. Med. Chem., 34:5-30 (1999)	
	12	REGISTER et al., J. Steroid Biochem. Mol. Biol., 64(3-4):187-191 (1998)	
	13	UEDA et al., J. Biol. Chem., 274(17):12124-12128 (1999)	
	14	YASUDA et al., J. Biol. Chem., 273(34):21958-21965 (1998)	

Examiner	Date	
Signature		
Oignature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. WC 9046021 v1

2 2002

ECH CENTER 1600/290

SEP

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.